Goereci, Yasemin
Ellenberger, David
Rommer, Paulus
Dunkl, Veronika
Golla, Heidrun
Zettl, Uwe
Stahmann, Alexander
Warnke, Clemens http://orcid.org/0000-0002-3510-9255
Funding for this research was provided by:
Innovationsfonds G-BA (01VSF19029)
Universitätsklinikum Köln
Article History
Received: 13 February 2024
Revised: 26 February 2024
Accepted: 28 February 2024
First Online: 22 March 2024
Declarations
:
: Yasemin Goereci, Veronika Dunkl and Heidrun Golla have nothing to disclose. David Ellenberger is an employee of the German MS Registry. Paulus Rommer received honoraria for consultancy/speaking from Alexion, Almirall, Amicus, Biogen, Merck Healthcare, Novartis, Roche, Sandoz, Sanofi-Genzyme, and TEVA. He has received research grants from Amicus, Biogen, Merck Healthcare, and Roche. Uwe K. Zettl has received speaking fees, travel support and /or financial support for research activities from Alexion, Almirall, Bayer, Biogen, Bristol-Myers-Squibb, Janssen, Merck Serono, Novartis, Octapharm, Roche, Sanofi-Genzyme, Teva as well as EU, BMBF, BMWi and DFG. Alexander Stahmann is the leader of the German MS Registry, which receives funding from a range of public and corporate sponsors, recently including G-BA, the German MS Trust, German MS Society, Biogen, Bristol-Myers Squibb, Merck, Novartis and Roche. Clemens Warnke has received institutional support from Novartis, Biogen, Alexion, Janssen, Hexal and Roche.